Verve Therapeutics (VERV) Stock Forecast & Price Target

$11.13 0.00 (0.00%)

As of 07/25/2025

Verve Therapeutics - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Hold

Based on 9 Analyst Ratings

Sell
0

Hold
6

Buy
3

Based on 9 Wall Street analysts who have issued ratings for Verve Therapeutics in the last 12 months, the stock has a consensus rating of "Hold." Out of the 9 analysts, 6 have given a hold rating, and 3 have given a buy rating for VERV.

Consensus Price Target

$14.57
30.92% Upside

According to the 9 analysts' twelve-month price targets for Verve Therapeutics, the average price target is $14.57. The highest price target for VERV is $24.00, while the lowest price target for VERV is $11.00. The average price target represents a forecasted upside of 30.92% from the current price of $11.13.

Get the Latest News and Ratings for VERV and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Verve Therapeutics and its competitors.

VERV Analyst Ratings Over Time

Type	Current Forecast 8/8/24 to 8/8/25	1 Month Ago 7/9/24 to 7/9/25	3 Months Ago 5/10/24 to 5/10/25	1 Year Ago 8/9/23 to 8/8/24
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	3 Buy rating(s)	3 Buy rating(s)	6 Buy rating(s)	6 Buy rating(s)
Hold	6 Hold rating(s)	6 Hold rating(s)	0 Hold rating(s)	2 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$14.57	$14.57	$25.75	$33.00
Forecasted Upside	30.92% Upside	31.39% Upside	508.75% Upside	506.62% Upside
Consensus Rating	Hold	Hold	Buy	Moderate Buy

VERV Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

VERV Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Verve Therapeutics Stock vs. The Competition

Type	Verve Therapeutics	Medical Companies	S&P 500
Consensus Rating Score	2.33	2.81	2.53
Consensus Rating	Hold	Moderate Buy	Moderate Buy
Predicted Upside	30.92% Upside	12,698.53% Upside	14.09% Upside
News Sentiment Rating	Positive News See Recent VERV News	Neutral News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
6/27/2025	BMO Capital Markets 4 of 5 stars	Kostas Biliouris Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform	$20.00 ➝ $13.50	+19.63%
6/18/2025	Jefferies Financial Group 2 of 5 stars	Roger Song Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$28.00 ➝ $11.00	-3.34%
6/18/2025	Lifesci Capital 2 of 5 stars	Cory Jubinville Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold	$12.00	+5.45%
6/18/2025	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Mitchell Kapoor Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$13.50	+18.63%
6/17/2025	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Myles Minter Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Market Perform
6/17/2025	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Whitney Ijem Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold	$39.00 ➝ $13.00	+18.45%
4/15/2025	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Etzer Darout Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$18.00 ➝ $24.00	+373.19%
4/15/2025	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Rick Bienkowski Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Overweight
3/4/2025	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Luca Issi Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Outperform ➝ Outperform	$17.00 ➝ $15.00	+160.78%
4/3/2024	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$56.00 ➝ $40.00	+378.47%
Get the Latest News and Ratings for VERV and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Verve Therapeutics and its competitors with MarketBeat's FREE daily newsletter.
8/11/2023	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Neutral ➝ Neutral	$31.00	+72.22%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 02:36 PM ET.

VERV Forecast - Frequently Asked Questions

: According to the research reports of 9 Wall Street equities research analysts, the average twelve-month stock price forecast for Verve Therapeutics is $14.57, with a high forecast of $24.00 and a low forecast of $11.00.
: 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Verve Therapeutics in the last year. There are currently 6 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" VERV shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in VERV, but not buy additional shares or sell existing shares.
: According to analysts, Verve Therapeutics's stock has a predicted upside of 30.92% based on their 12-month stock forecasts.
: Over the previous 90 days, Verve Therapeutics's stock had 6 downgrades by analysts.
: Verve Therapeutics has been rated by research analysts at BMO Capital Markets, Canaccord Genuity Group, HC Wainwright, Jefferies Financial Group, Lifesci Capital, and William Blair in the past 90 days.
: Analysts like Verve Therapeutics less than other "medical" companies. The consensus rating for Verve Therapeutics is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how VERV compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top-Rated Stocks

More Ratings Tools

This page (NASDAQ:VERV) was last updated on 8/8/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Verve Therapeutics (VERV) Stock Forecast & Price Target